Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$63.74 USD
+1.37 (2.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $63.73 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.74 USD
+1.37 (2.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $63.73 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Zacks News
Bull of the Day: Edwards Lifesciences (EW)
by Kevin Cook
The world leader in non-surgical heart valve replacement keeps the "beat and raise" going with innovation and execution
Here's Why Investors Should Buy Amedisys (AMED) Right Now
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Align Technology's Invisalign Sales Strong Amid Margin Woes
by Zacks Equity Research
Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.
LabCorp Partners OmniSeq to Grow in Immuno-Oncology Space
by Zacks Equity Research
LabCorp (LH) decides to distribute OmniSeq's molecular diagnostics assays in the United States and beyond to grow in immuno-oncology space.
CVS Health (CVS) Releases Encouraging Flu Shot Survey Data
by Zacks Equity Research
CVS Health's (CVS) survey on flu vaccination came up with positive outcome. The data confirms untapped opportunities in the flu vaccine market.
Here's Why Investors Should Buy BioTelemetry (BEAT) Now
by Zacks Equity Research
BioTelemetry's (BEAT) buyout of LifeWatch AG has expanded its product portfolio and customer base in the cardiac monitoring and diagnostic services space.
Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA
by Zacks Equity Research
Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.
4 Stocks to Buy as Q2 Earnings Season Nears Close
by Tirthankar Chakraborty
Earnings growth is considered to be the most significant variable in influencing the share price.
Accelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%
by Zacks Equity Research
Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise more than 5% on the day.
Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics
by Zacks Equity Research
Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.
Allscripts, Elligo Health Enter in Strategic Partnership
by Zacks Equity Research
Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.
Walgreens' (WBA) Research Website to Add Value in Healthcare
by Zacks Equity Research
Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.
Omnicell Upgrades Web Portal, Grows in Medication Management
by Zacks Equity Research
Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.
Henry Schein to Offer CAEK's HIPAA Software LayerCompliance
by Zacks Equity Research
Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.
Here's Why Investors Should Buy Edwards Lifesciences Now
by Zacks Equity Research
Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments, with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
Is Edwards Lifesciences Corporation (EW) a Great Growth Stock?
by Zacks Equity Research
Edwards Lifesciences Corporation (EW) is a company that might be well-positioned for future earnings growth.
Here's Why Investors Should Buy Align Technology (ALGN) Now
by Zacks Equity Research
Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.
Abbott-North West London Pathology Expand in Diagnostics
by Zacks Equity Research
Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.
Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study
by Zacks Equity Research
Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.
Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish
by Zacks Equity Research
Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.
Varian (VAR) Rides on Oncology and Proton Therapy Businesses
by Zacks Equity Research
Varian Medical's (VAR) oncology and Proton therapy business' growth prospects remain impressive. However, competition in the radiotherapy space raise concern.
Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.